Introduction As of 23 September 2022, the COVID-19stastistics in India are:Total cases: 4,45,43,089Total recovered: 4,39,67,340Active cases: 47,379Total deaths: 5,28,370Total vaccinated: 2,16,83,24,537Covishield, manufactured by Serum Institute of India (SII) in partnership with AstraZeneca, accounted for some 80 per cent of doses. Covaxin, manufactured by Hyderabad-based Bharat Biotech, accounted for a significant part of the rest followed by Biological E's, Corbevax and Russia's Sputnik V. .Latest Updatese The Drugs Controller General of India (DCGI) approved Corbevax as a precaution (booster) dose for those aged 18 and above who are double vaccinated with either Covishield or Covaxin.e People who have two doses of Sputnik V and are unable to get a booster dose due to supply related problems can receive Covaxin or Covishield as a precautionary dose.e The three-dose ZyCoV-D vaccine is also India's first needle-freeCOVID-19 jab is administered with a disposable needle-free injector, which uses a narrow stream of the fluid to penetrate the skin and deliver the jab to the proper tissue.e In September 2022, Bharat Biotech announced that its iNCOVACC (BBV154), the world's first intranasal COVID-19 vaccine, has received approval from the Drugs Controller General of India for restricted use in emergencies for those 18 and older. Mucosal vaccines target thin membranes that line the nose, mouth and lungs. They are administered by contact with linings of the body's barrier organs through drops, sprays, or swallowed capsules. By prompting an immune response where the virus first enters the body, researchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people, something current COVID-19 shots are unable to do. This means early clearance of the virus from the body before its spread to lungs and other organs is a distinct possibility and an advantage over other intramuscular injectable vaccines.e Reliance Life Sciences has completed the Phase 1 clinical trials of the two- dose COVID-19 vaccine soon. Formal approval for studies is soon expected. The study was conducted on a small group of 20-80 people with RNA based vaccine. As the vaccine is a protein subunit vaccine, it is expected to be safe for all age groups. Other vaccinesA recent study conducted in Israel has shown that after two doses of Tozinameran from Pfizer-BioNTech, the vaccine provides95.3 per cent protection against the infection and significantly reduces the risk of death. The US FDA has authorised a booster dose in adults who have beenpreviously vaccinated. A recent report has stated that the Indian Government is not willing to import and purchase Tozinameran as domestic output for more affordable vaccines has increased significantly.Moderna's vaccine has been found to remain stable at -20° Celsius for up to six months. It can be stored in a refrigerator at 4° Celsius for up to 30 days. The Phase 3 clinical trials of the vaccine have shown94.1 per cent efficacy in preventing COVID-19 infection and complete protection against severe forms of thedisease. Moderna has received emergency- use authorisation in India in partnership with Cipla. A recent report has stated that the Indian Government is not willing to import and purchase Moderna's vaccine as domestic output for more affordable vaccines has increased significantly..Janssen Pharmaceutical Companies of Johnson & Johnson has also partnered with Indian pharmaceutical company Biological E for the manufacturing of a single dose COVID 19 vaccine. The vaccine can be stored at a temperature of 2 to 8° Celsius for up to 3 months. The vaccine has received emergency use authorisation in India. The company is soon expected to commence its commercial export of vaccines after approval from DCGI. The vaccine will not be administered in India as the government did not agree to the company's indemnity against legal liability.Things to rememberHere are a few things to keep in mind while getting vaccinated for COVID 19 disease:e Pregnant women in India are advised to take either the Covishield, Covaxin or Sputnik vaccine by the health advisories and medical authorities in India.e On the day of vaccination, inform your vaccination officer about your health condition and medication to avoid any complications.e Observe any side effects after vaccination and keep your physician informed about them. Please Note: Diabetes Health recommends readers dial the central helpline no - 011-23978046 -for up-to-date information and guidance on Covid-19 vaccination.
Introduction As of 23 September 2022, the COVID-19stastistics in India are:Total cases: 4,45,43,089Total recovered: 4,39,67,340Active cases: 47,379Total deaths: 5,28,370Total vaccinated: 2,16,83,24,537Covishield, manufactured by Serum Institute of India (SII) in partnership with AstraZeneca, accounted for some 80 per cent of doses. Covaxin, manufactured by Hyderabad-based Bharat Biotech, accounted for a significant part of the rest followed by Biological E's, Corbevax and Russia's Sputnik V. .Latest Updatese The Drugs Controller General of India (DCGI) approved Corbevax as a precaution (booster) dose for those aged 18 and above who are double vaccinated with either Covishield or Covaxin.e People who have two doses of Sputnik V and are unable to get a booster dose due to supply related problems can receive Covaxin or Covishield as a precautionary dose.e The three-dose ZyCoV-D vaccine is also India's first needle-freeCOVID-19 jab is administered with a disposable needle-free injector, which uses a narrow stream of the fluid to penetrate the skin and deliver the jab to the proper tissue.e In September 2022, Bharat Biotech announced that its iNCOVACC (BBV154), the world's first intranasal COVID-19 vaccine, has received approval from the Drugs Controller General of India for restricted use in emergencies for those 18 and older. Mucosal vaccines target thin membranes that line the nose, mouth and lungs. They are administered by contact with linings of the body's barrier organs through drops, sprays, or swallowed capsules. By prompting an immune response where the virus first enters the body, researchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people, something current COVID-19 shots are unable to do. This means early clearance of the virus from the body before its spread to lungs and other organs is a distinct possibility and an advantage over other intramuscular injectable vaccines.e Reliance Life Sciences has completed the Phase 1 clinical trials of the two- dose COVID-19 vaccine soon. Formal approval for studies is soon expected. The study was conducted on a small group of 20-80 people with RNA based vaccine. As the vaccine is a protein subunit vaccine, it is expected to be safe for all age groups. Other vaccinesA recent study conducted in Israel has shown that after two doses of Tozinameran from Pfizer-BioNTech, the vaccine provides95.3 per cent protection against the infection and significantly reduces the risk of death. The US FDA has authorised a booster dose in adults who have beenpreviously vaccinated. A recent report has stated that the Indian Government is not willing to import and purchase Tozinameran as domestic output for more affordable vaccines has increased significantly.Moderna's vaccine has been found to remain stable at -20° Celsius for up to six months. It can be stored in a refrigerator at 4° Celsius for up to 30 days. The Phase 3 clinical trials of the vaccine have shown94.1 per cent efficacy in preventing COVID-19 infection and complete protection against severe forms of thedisease. Moderna has received emergency- use authorisation in India in partnership with Cipla. A recent report has stated that the Indian Government is not willing to import and purchase Moderna's vaccine as domestic output for more affordable vaccines has increased significantly..Janssen Pharmaceutical Companies of Johnson & Johnson has also partnered with Indian pharmaceutical company Biological E for the manufacturing of a single dose COVID 19 vaccine. The vaccine can be stored at a temperature of 2 to 8° Celsius for up to 3 months. The vaccine has received emergency use authorisation in India. The company is soon expected to commence its commercial export of vaccines after approval from DCGI. The vaccine will not be administered in India as the government did not agree to the company's indemnity against legal liability.Things to rememberHere are a few things to keep in mind while getting vaccinated for COVID 19 disease:e Pregnant women in India are advised to take either the Covishield, Covaxin or Sputnik vaccine by the health advisories and medical authorities in India.e On the day of vaccination, inform your vaccination officer about your health condition and medication to avoid any complications.e Observe any side effects after vaccination and keep your physician informed about them. Please Note: Diabetes Health recommends readers dial the central helpline no - 011-23978046 -for up-to-date information and guidance on Covid-19 vaccination.
